Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

believe that utilization of this cutting edge technology sets the combination apart from subcutaneous delivery of Cinryze without rHuPH20, and increases the likelihood of successful clinical development. It could improve flexibility and convenience, and potentially allow prevention-minded patients living with HAE to self administer every three or four days, just as they do today with the current IV formulation, but with a single subcutaneous injection."  

This open-label multiple-dose study was conducted in 12 subjects with HAE who previously participated in the ViroPharma Phase 2 trial evaluating the pharmacokinetics of subcutaneous injections of Cinryze when given alone relative to intravenous infusion.  Qualified subjects participated in a single 18-day study period, followed by a 30-day post-treatment follow-up.  A 1000 U or 2000 U dose of Cinryze in combination with rHuPH20 was administered as a single subcutaneous injection, two times weekly, allowing within-subject comparison across the different methods of administration.  Additional information about this Phase 2 subcutaneous Cinryze clinical trial can be found at clinicaltrials.gov.

Halozyme's proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. When injected under the skin, rHuPH20 transiently generates channels in tissues underlying the outer layers of the skin to increase the absorption and spread of injected drugs. 

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedem
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the ... announces the following financial results for its third quarter of ... 30, 2014: , Revenue of $1,291,378, a 13% ... , Net loss for the quarter of $240,156 compared to ... prior year For the nine months ended ...
(Date:8/27/2014)... 27, 2014  After the February 2014 launch of ... solution for medical practices and management companies, Prime ... new software. "The feedback has been great," ... "The sheer number of demos and new sign-ups is ... for these types of software features." ...
(Date:8/27/2014)... , Aug. 27, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , today announced the results of the Company,s ... 2014 in Beijing , PRC. The required quorum, ... The Company,s shareholders approved the following proposals:  ... Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... derivative compound series,show highly selective PI3K-inhibition which ... 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris,Inc. , ... on,endocrine therapy and oncology, today presented an ... pyridopyrazine derivatives,with high selectivity for PI3K inhibition, ...
... With Improved Potential to,Battle Their Disease, PASADENA, ... Inc., a majority-owned subsidiary of Arrowhead,Research Corporation ... will be featured in a poster presentation ... (AACR) Annual,Meeting. In particular, this poster includes ...
Cached Medicine Technology:AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
(Date:8/27/2014)... last time you experienced worrisome medical symptoms, did ... health-care professional? If so, you,re not alone. Consumers ... peer support groups to gather anecdotal information and ... and trustworthy sources. New research to be presented ... studies the characteristics of consumers who use the ...
(Date:8/27/2014)... August 27, 2014 Will Holbrook, CP ... Will has over 15 years of experience in ... in Rome, Georgia with a Bachelor of Science degree ... chemistry. He received his graduate degree in prosthetics ... excited to have Will join us at Fourroux,” says ...
(Date:8/27/2014)... -- In a new study done from the heights ... pressure steadily increases if you ascend to great heights. ... to treat high blood pressure was ineffective once climbers ... online Aug. 27 in the European Heart Journal ... at sea level who have sleep apnea, in which ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... enhancement and protection services for hospitals, is pleased to ... Inc. 5000 List of America’s Fastest-Growing Companies. The list ... of the economy—America’s independent entrepreneurs. , "It's been ... honored to be included in this year's Inc. 5000 ...
(Date:8/27/2014)... 2014 The American Brain Tumor ... the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant ... ABTA is seeding the field with talented, bright young ... of the causes, effects, diagnosis and treatment of brain ... committee based on the potential to advance the understanding ...
Breaking Medicine News(10 mins):Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3
... the tourist resort city of Livingstone were tested for bird ... backyards'. // ,Simon Miti, the permanent secretary at ... thorough investigation of the outbreak'. ,The number of ... residents who cooked and ate the dead chickens have been ...
... is found to enhance educational achievements and combat other behavioral ... that it has a positive effect on the kids suffering ... responded better to Omega 3 fish oils than to the ... found that fish oil is very essential for the kids. ...
... the killer of Lin and Megan Russell has petitioned the High ... public since it would be misused by the press. ... committed a decade ago. Stone's lawyer, Richard Clayton QC said that ... be seriously misused by the tabloid press. ,Mr Clayton ...
... Delhi Police summoned three doctors of the Indraprastha Apollo ... //on the condition of Rahul Mahajan, who was admitted ... overdose. ,"We have summoned the doctors and ... of police, heading the probe against the hospital. ...
... introduce a common school system in the country, educationists ... the primary education //system and remove disparities among students. ... school system in the country so that all students ... students," said Madhu Prasad, educationist and a professor in ...
... According to a new study published in the Journal ... epileptic seizures by inducing rhythmical //electrical activity in the ... the hippocampus. The researchers found that, by imposing a ... reduce epileptic seizures by 86-97%. ,The study ...
Cached Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: